An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

Part of paid clinical trials in Orlando, Florida.

Sponsor
Relypsa, Inc.
Study ID
NCT02033317
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • patiromer — DRUG
    15 grams/day (5 grams 3 times daily) administered orally

Study Details

This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis.

Key Dates

Start date
Aug 31, 2008
Status verified
May 2021
Primary completion
Dec 31, 2008
Completion
Dec 31, 2008

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: patiromer

Primary Outcome Measure

Change in Serum Potassium (Day 1 to Day 8) [ Time Frame: Day 1 and Day 8 ]

Locations (2)

FacilityCityStateZIPSite coordinators
Investigator SiteOrlandoFlorida32809-
Investigator SiteMinneapolisMinnesota55404-

Find similar trials in Orlando, FL

By research site
Investigator Site· Orlando, FLInvestigator Site· Minneapolis, MN

Related Studies